Brazil: ANVISA

The national authority

ANVISA - the Agencia Nacional de Vigilancia Sanitaria - is Brazil's national health regulatory agency, linked to the Ministry of Health. It regulates medicines, medical devices, food, cosmetics, and health services across the country, and it operates within Brazil's unified national health system, which gives its decisions unusual reach into both private markets and public procurement.

Brazil is the largest pharmaceutical market in Latin America, so ANVISA's decisions carry weight well beyond its borders: several neighboring systems watch and often follow its assessments.

How products enter the market

Medicines require a marketing registration (registro) granted after evaluation of quality, safety, and efficacy data. Lower-risk products such as many over-the-counter medicines and some devices follow a lighter notification route rather than full registration.

Medical devices are classified into four risk classes - I through IV - with class determining whether the product needs notification or full registration with supporting technical evidence. In-vitro diagnostics follow the same risk logic.

A distinctive feature: price approval for medicines runs through a separate interministerial medicines market regulation chamber, so market entry in Brazil has both a technical regulator and a price regulator.

Manufacturing and reliance

Brazilian rules require manufacturers - domestic and foreign - to hold Brazilian good manufacturing practice certification before products can be registered, and foreign sites face inspection. This has historically made the manufacturing authorization a pacing item for market entry.

In recent years ANVISA has moved toward reliance: it can optimize review by considering assessments from trusted foreign regulators for certain product types, part of a broader modernization of its review system.

Clinical trial authorization runs through a combined pathway involving ANVISA and the national research ethics system, reflecting Brazil's strong ethics-review tradition.

Using this profile

Administrators and researchers should note that ANVISA publishes extensively but primarily in Portuguese; the English section of its portal is a useful entry point but covers less than the Portuguese site. Registration status, product classifications, and recalls are published in official databases and in the federal official gazette.

For cross-country comparison: ANVISA is among the authorities assessed by the World Health Organization as operating at a high performance level, and its framework - four-class devices, registration vs notification split, active pharmacovigilance - aligns with international models while keeping distinct Brazilian features such as separate price regulation. The authority portal listed in this profile's internal reference record is the primary source for current rules.